SGLT-2抑制剂心血管安全性 达格列净(dapagli?ozin)是最早研发并全球第一个 SGLT-2 抑制剂,也是目前临床研究证据最多,在心血管安全性评价较为全面的 SGLT-2 抑制剂。 达格列净已完成的IIb和III期临床研究显示:相比安慰剂,达格列净并不增加主要心血管不良事件(Major adverse cardiovascular events,MACE)发生率[1]...
[8] FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2018. [9] Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in d...
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy vs. placebo or active comparator ...
We assessed the impact of SGLT2 inhibitors on cellular senescence induced by high fat and high glucose. Methods Mouse model of DCM and drug administration Male C57BL/6J mice (6-8weeks old, 22 ± 2 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. After...
Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better. ...
Are SGLT2-inhibitors a diabetes drug or a drug for HF and CKD? Despite multiple guideline recommended disease-modifying therapies, patients with HF continue to have a poor prognosis [54]. Results from recent CV and renal outcome trials are very promising highlighting SGLT2-inhibitors' potential ...
The drug effect on myocardial infarction is still a topic of meaningful investigation [14]. The data presented herein indicated that SGLT2 inhibitors should be considered in populations with type 2 diabetes for AF/AFL prevention, given that they safely reduced HbA1c, body weight, and blood ...
Determining your patient’s suitability for SGLT2 inhibitors Recognising adverse reactions and how you should respond Understanding drug interactions Attend this online NHS event from the comfort of your own home Take an hour out to focus on the main considerations from prescribing to ongoing management...
This finding is indeed intriguing given the established role of glycolysis in cancer cell survival. Canagliflozin has additive anti-proliferative efficacy over specific OxPhos inhibitors indicating that this drug engages additional molecular pathways in its anti-proliferative action beyond metabolic stress ...
(SGLT-2) inhibitors present potent nephroprotective properties. In clinical trials in patients with type 2 diabetes mellitus, these agents were shown to reduce albuminuria and proteinuria by 30–50% and the incidence of composite hard renal outcomes by 40–50%. Furthermore, their mechanism of ...